Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
2 citations
,
February 2018 in “International Research Journal of Pharmacy” Eclipta alba leaf alkaloids may help treat HIV by inhibiting the virus's activity.
October 2025 in “Dermatology and Therapy” 11 citations
,
January 2017 in “Skin Appendage Disorders” Use lower concentrations of triamcinolone acetonide to reduce steroid-induced scalp atrophy.
5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
July 2022 in “Journal of Cosmetic Dermatology” Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
16 citations
,
January 2021 in “Journal of the American Academy of Dermatology” Asynchronous telemedicine for acne treatment is effective and improves access and productivity.
15 citations
,
June 1961 in “Archives of Dermatology” Triamcinolone can regrow hair in alopecia areata, but the effect is temporary.
5 citations
,
July 2007 in “PubMed” An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
2 citations
,
May 2024 in “The Turkish Journal of Gastroenterology” Tacrolimus treatment for autoimmune hepatitis can cause hair loss.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
25 citations
,
January 2006 in “Pharmacoepidemiology and drug safety” SSRIs can cause hair loss, especially sertraline, with higher risk in women.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
September 2015 in “Journal watch” Triamcinolone acetonide injections help regrow hair in alopecia areata patients.
1 citations
,
January 2014 in “Side effects of drugs annual” Antihelminthic drugs treat worm infections but face challenges like low treatment coverage and potential drug resistance, with various side effects reported for different drugs.
37 citations
,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
18 citations
,
September 1979 in “DMW - Deutsche Medizinische Wochenschrift” Diane is effective for treating acne, seborrhoea, androgenic alopecia, and mild hirsutism in women.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet”
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
October 2025 in “Electronic Theses and Dissertations Repository (University of Pisa)” Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.